The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
about
A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor proteinIdentification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alphaHypoxia-inducible factors in the kidneyDevelopmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau diseaseVHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinomaThe role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesisOne hit, two outcomes for VHL-mediated tumorigenesis.Deletion of the von Hippel-Lindau gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development.VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regenerationNek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.A mouse model to study the link between hypoxia, long QT interval and sudden infant death syndrome.Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiencyLoss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma.The von Hippel-Lindau gene: turning discovery into therapy.Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGFNervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.Carotid body oxygen sensing and adaptation to hypoxia.Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.The hypoxia-inducible factor-C/EBPα axis controls ethanol-mediated hepcidin repression.Epidermal sensing of oxygen is essential for systemic hypoxic responseLoss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development.Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor.Vascular biology and pathobiology of the liver: Report of a single-topic symposium.Regulation of Bone Marrow Angiogenesis by Osteoblasts during Bone Development and Homeostasis.Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.Fibrosis and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma.Pathology of the Nervous System in Von Hippel-Lindau Disease.
P2860
Q24299850-0B1E7293-1F82-4DE3-A2B3-61FDB87AEB8EQ24651502-1D45A19F-0877-4537-BA6F-15FA4C495C89Q28303287-93994104-B28D-449B-9C16-1EC1E502F080Q30430557-A72E76A2-0D81-4E0D-8F22-1D6FE8365AE2Q33816341-D62D0F77-501E-4717-A58B-2B0C13C827CDQ34064359-5C6D9EDB-2556-4AF5-AA70-A3AFDD9F3F82Q34235680-B258012A-D8A0-40DB-93E4-791A1EDC21A9Q34580977-4626E7B8-D2D4-45FC-B370-52227599E292Q34843093-66978871-AD86-4520-A5F5-F89F0BF4CFE9Q34880963-CB183B2E-984F-4CC5-82E2-BEBD64FB250AQ35813751-85B76052-C3BE-4920-A79E-4A9F8A2E111AQ36127410-D3627EB5-85B6-4C08-AD5A-6A4904C41DB9Q36392988-35498EDD-4EA3-46E8-AF33-5A5958DFFA9CQ36604618-B2899543-18DE-4AA4-B33F-000A88971A18Q36683101-EB80377E-A808-446C-94EC-29CC45A431F0Q37137793-98AF8117-087D-463B-AFB8-3CABE7A5C409Q37224635-F903F02A-913B-441F-BD6D-219ECE1D7636Q37272653-FF2E733E-3E5B-4101-BBF6-512A27CA6DCEQ37532524-FABA709A-8D76-4323-86E9-20B2C5C2C4A0Q38080737-CDF243A7-E282-4BDB-884B-D5D764EDF3CBQ38587534-036B66EC-6910-4BC9-B189-435EF151A2C6Q39042077-C10CF5DD-2DD1-4BB4-913F-59CFE74A7DDCQ39290479-2616E872-ED8F-4913-ADE7-1E265403EB34Q39301385-05FEDDAF-EADA-470B-BA06-9F82DA9B7B5BQ39902159-1DC4350B-17EE-4890-AB1B-2E200F0D154FQ41995211-825E349C-1818-441F-A775-BE6B62F60B67Q42201994-8A97F085-E76B-4CC8-B888-BFADAF73134FQ43073192-8106AA06-AD27-40C0-ABA6-166AB0C3E8CCQ43099001-C954CE9B-E336-447D-8D04-DD883D19BAD3Q45868480-D17DE8C1-6C9D-45A0-BC70-1147227CB13BQ46915042-D5FBFCF2-68A9-4584-9263-318BAC3F6FF6Q52590924-B45FBFCD-1D11-40E3-90D7-B8336A5ABA88Q52979101-0910E683-E9D1-443D-8016-0234A2B98798
P2860
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The VHL tumor suppressor in de ...... by conditional gene targeting.
@ast
The VHL tumor suppressor in de ...... by conditional gene targeting.
@en
type
label
The VHL tumor suppressor in de ...... by conditional gene targeting.
@ast
The VHL tumor suppressor in de ...... by conditional gene targeting.
@en
prefLabel
The VHL tumor suppressor in de ...... by conditional gene targeting.
@ast
The VHL tumor suppressor in de ...... by conditional gene targeting.
@en
P2860
P1476
The VHL tumor suppressor in de ...... by conditional gene targeting
@en
P2093
Volker H Haase
P2860
P304
P356
10.1016/J.SEMCDB.2005.03.006
P577
2005-04-26T00:00:00Z